{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-25-000013","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.529268+00:00","generated_at":"2026-05-27T04:00:47.473249+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Serina Therapeutics closes $5M second tranche of equity financing at 113% premium","bullets":["Received second $5M tranche of $10M equity financing from JuvVentures (UK) Limited.","Issued 500,000 shares at $10/share (113% premium to Jan 31 close of $4.70).","Issued warrants for 755,728 shares at $18.00 per share.","Funds to advance SER-252 (POZ-apomorphine) into Phase 1 trial in advanced Parkinson's in H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-25-000013","json":"https://secwatch.observer/filing/0001708599-25-000013.json","markdown":"https://secwatch.observer/filing/0001708599-25-000013.md","text":"https://secwatch.observer/filing/0001708599-25-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000013/0001708599-25-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000013/ser-20250203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T04:00:47.473249+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}